Gilead Acquires Global Rights to PepStar's HCXT-2001 for $1.275 Billion Upfront

Gilead Sciences has agreed to acquire PepStar Therapeutics' oral IL-23R inhibitor program, including Phase 1 candidate HCXT-2001, for a cash upfront payment of $1.275 billion. Gilead gains worldwide development rights to the program, with the deal expected to close in the fourth quarter of 2026. YuanBio Venture Partners invested in PepStar's Series A round in March 2026.